Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study.

Kumarathurai P, Anholm C, Fabricius-Bjerre A, Nielsen OW, Kristiansen O, Madsbad S, Haugaard SB, Sajadieh A

Journal of hypertension1 May 2017Cited by 30 (Europe PMC)

PMID28129251DOI10.1097/hjh.0000000000001275PepBankPUB-28129251

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and stable coronary artery disease, liraglutide did not significantly change mean 24-h systolic blood pressure compared with placebo.
In plain wordsIn adults with type 2 diabetes and heart disease, liraglutide did not change average 24-hour systolic blood pressure compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeMean 24-h systolic blood pressure
Study
n = 24
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Mean 24-h SBP difference
1.8 mmHg
liraglutide vs placebo
Source sentences
Summary
Liraglutide, when compared with placebo, did not induce any significant changes in mean 24-h SBP [difference +1.8 mmHg (95% confidence interval, 95% CI: -4.33 to 7.93)] or DBP [+4.2 mmHg (-0.74 to 9.17)].
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-one patients with type 2 diabetes and stable coronary artery disease were randomized to receive liraglutide or placebo to a backbone therapy of metformin in this double-blind, placebo-controlled 12 along with 12 weeks crossover study.
Summary · context
Twenty-four individuals completed all 24-h BP measurements.
Report a problemFND-2812925101
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and stable coronary artery disease, liraglutide did not significantly change mean 24-h diastolic blood pressure compared with placebo.
In plain wordsIn adults with type 2 diabetes and heart disease, liraglutide did not change average 24-hour diastolic blood pressure compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeMean 24-h diastolic blood pressure
Study
n = 24
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Mean 24-h DBP difference
4.2 mmHg
liraglutide vs placebo
Source sentences
Summary
Liraglutide, when compared with placebo, did not induce any significant changes in mean 24-h SBP [difference +1.8 mmHg (95% confidence interval, 95% CI: -4.33 to 7.93)] or DBP [+4.2 mmHg (-0.74 to 9.17)].
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-one patients with type 2 diabetes and stable coronary artery disease were randomized to receive liraglutide or placebo to a backbone therapy of metformin in this double-blind, placebo-controlled 12 along with 12 weeks crossover study.
Summary · context
Twenty-four individuals completed all 24-h BP measurements.
Report a problemFND-2812925102
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and stable coronary artery disease, liraglutide showed a trend for higher evening systolic blood pressure than placebo.
In plain wordsIn adults with type 2 diabetes and heart disease, evening systolic blood pressure tended to be higher with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
IncreaseEvening systolic blood pressure
Study
n = 24
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Evening SBP difference
9.2 mmHg
liraglutide vs placebo
Source sentences
Summary
Twenty-four-hour BP profiles revealed a trend for increase in evening SBP and DBP [+9.2 mmHg (95% CI: 1.1-17.2) and +9.7 mmHg (95% CI: 3.9-15.5), respectively].
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-one patients with type 2 diabetes and stable coronary artery disease were randomized to receive liraglutide or placebo to a backbone therapy of metformin in this double-blind, placebo-controlled 12 along with 12 weeks crossover study.
Summary · context
Twenty-four individuals completed all 24-h BP measurements.
Report a problemFND-2812925103
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and stable coronary artery disease, liraglutide showed a trend for higher evening diastolic blood pressure than placebo.
In plain wordsIn adults with type 2 diabetes and heart disease, evening diastolic blood pressure tended to be higher with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
IncreaseEvening diastolic blood pressure
Study
n = 24
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Evening DBP difference
9.7 mmHg
liraglutide vs placebo
Source sentences
Summary
Twenty-four-hour BP profiles revealed a trend for increase in evening SBP and DBP [+9.2 mmHg (95% CI: 1.1-17.2) and +9.7 mmHg (95% CI: 3.9-15.5), respectively].
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-one patients with type 2 diabetes and stable coronary artery disease were randomized to receive liraglutide or placebo to a backbone therapy of metformin in this double-blind, placebo-controlled 12 along with 12 weeks crossover study.
Summary · context
Twenty-four individuals completed all 24-h BP measurements.
Report a problemFND-2812925104
05HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes and stable coronary artery disease, mean heart rate increased significantly after liraglutide.
In plain wordsIn adults with type 2 diabetes and heart disease, liraglutide raised the average heart rate.
Peptide
Liraglutide
Outcome
IncreaseMean heart rate
Study
n = 24
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Heart rate difference
7.6 bpm
liraglutide vs placebo
Source sentences
Summary
Mean heart rate significantly increased after liraglutide [+7.6 bpm (95% CI: 2.56-12.62)].
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-one patients with type 2 diabetes and stable coronary artery disease were randomized to receive liraglutide or placebo to a backbone therapy of metformin in this double-blind, placebo-controlled 12 along with 12 weeks crossover study.
Summary · context
Twenty-four individuals completed all 24-h BP measurements.
Report a problemFND-2812925105
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and stable coronary artery disease, liraglutide did not affect blood pressure variability.
In plain wordsIn adults with type 2 diabetes and heart disease, liraglutide did not change how much blood pressure varied.
Peptide
Liraglutide
Outcome
No significant changeBlood pressure variability
Study
n = 24
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide did not affect the BP variability
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-one patients with type 2 diabetes and stable coronary artery disease were randomized to receive liraglutide or placebo to a backbone therapy of metformin in this double-blind, placebo-controlled 12 along with 12 weeks crossover study.
Summary · context
Twenty-four individuals completed all 24-h BP measurements.
Report a problemFND-2812925106
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and stable coronary artery disease, liraglutide did not affect nocturnal blood pressure dipping.
In plain wordsIn adults with type 2 diabetes and heart disease, liraglutide did not change the usual night-time drop in blood pressure.
Peptide
Liraglutide
Outcome
No significant changeNocturnal blood pressure dipping
Study
n = 24
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide did not affect the BP variability or the nocturnal BP dipping.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty-one patients with type 2 diabetes and stable coronary artery disease were randomized to receive liraglutide or placebo to a backbone therapy of metformin in this double-blind, placebo-controlled 12 along with 12 weeks crossover study.
Summary · context
Twenty-four individuals completed all 24-h BP measurements.
Report a problemFND-2812925107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT01595789

The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes

Haugaard, Steen Bendix, M.D., DMScn = 41May 2012 to Jul 2015

Coronary Artery Disease · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 7 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.